Clovis Oncology, Inc.
Clovis Oncology, Inc. (CLVS): 2 pipeline candidates · ~5 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
5.3 months
D/E -1.83 · 0% dilution
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for Clovis Oncology, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$58.3M
Quarterly Burn
$40.6M
Runway
5.3 mo
Revenue
$30.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in Clovis Oncology, Inc.'s pipeline?
Clovis Oncology, Inc. (CLVS) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Clovis Oncology, Inc.'s lead drug candidate?
Clovis Oncology, Inc.'s most advanced tracked candidate is lucitanib (Phase 2).
What is Clovis Oncology, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Clovis Oncology, Inc. has approximately 5.3 months of cash runway.
Get the full picture on Clovis Oncology, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.